Previous 10 | Next 10 |
Black Diamond Therapeutics (NASDAQ:BDTX) on Monday said it would discontinue the development of its BDTX-189 product and reduce its workforce by about 30%. The company will focus on development of its BDTX-1535 and BDTX-4933 programs, along with other discovery efforts. BDTX-189 is a sma...
– Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP platform enabled small molecule drug discovery efforts – – Company to discontinue development of BDTX-189 and reduce workforce to extend its cash runway into 3Q 2024, supportin...
Black Diamond Therapeutics (NASDAQ:BDTX) said the first patient was dosed in a phase 1 trial of BDTX-1535 to treat non-small cell lung cancer (NSCLC) and glioblastoma (GBM), a type of brain cancer. “The dosing of the first patient in our Phase 1 study of BDTX-1535, a next generation br...
- Clinical update expected in second half of 2023 - CAMBRIDGE, Mass. and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announc...
CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. ...
CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Wendy L. Dixon, Ph.D., to its Board of...
Black Diamond Therapeutics press release (NASDAQ:BDTX): Q4 GAAP EPS of -$0.71 beats by $0.30. Cash, cash equivalents, and investments of $209.8 million as of December 31, 2021, expected to be sufficient to fund operations into 2024. For further details see: Black Diamond Therapeutics GA...
IND allowed by U.S. FDA and Phase 1 study of BDTX-1535 initiated for the treatment of GBM and NSCLC including those with CNS metastases Preclinical data demonstrating the potential of MasterKey programs BDTX-1535, CNS-BRAF (BDTX-4933), and FGFR presented at AACR-NCI-EORTC (ANE) ...
CAMBRIDGE, Mass. and NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. ...
CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Elizabeth Montgomery as its first Chief...
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
Black Diamond Therapeutics Inc. Website:
2024-07-31 09:00:12 ET Laura Prendergast from Raymond James issued a price target of $20.00 for BDTX on 2024-07-31 08:18:00. The adjusted price target was set to $20.00. At the time of the announcement, BDTX was trading at $5.91. The overall price target consensus is at ...
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...